Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-02-13
2007-02-13
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S173100, C530S387100, C530S387300, C530S388200, C530S388220, C530S388700, C530S388730
Reexamination Certificate
active
09576424
ABSTRACT:
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies, or B7.1-binding fragments thereof, may be used for the treatment of Crohn's disease.
REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5747034 (1998-05-01), De Boer et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 194 276 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: WO 87/01131 (1987-02-01), None
patent: WO 92/06193 (1992-04-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/09812 (1993-05-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 95/22619 (1995-08-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 96/40878 (1996-12-01), None
patent: WO 98/19706 (1998-05-01), None
Webster's II New Riverside University Dictionary The Riverside Publishing Company 1988 pp. 435 and 762.
Skowick et al. Trends in Biotechnology 18:34-39 (2000).
Kuntz Science 257:1078-1082 (1992).
Ngo et al. in the Protein Folding Problem and Tertiary Structure Prediction, 1998, Merz et al [Ed.], Birkhauser, Boston MA. pp. 433, 492-495.
Linsley, Peter S. et al., “T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-2.”Proc. Natl. Acad. Sci. USA, Jul. 1990, vol. 87, pp. 5031-5035.
Linsley, Peter S. et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,”J. Exp. Med., The Rockefeller University Press, Mar. 1991, vol. 173, pp. 721-729.
Liu et al., “Co-stimulation of murine CD4-T cell growht: coopeartion between B7 and heat-stable antigen,”Eur. J. Immunol., Nov. 1992, vol. 22, No. 11, pp. 2855-2859.
Inaba et al., “The tissue distribution of the B7-2 co-stimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro,”J. Exp. Med., Nov. 1994, vol. 180, No. 5, pp. 1849-1860.
Engel et al., “The B7-2 (B70) co-stimulatory molecule expressed by monocytes and actiated B lymphocytes is the CD86 differentiation antigen,”Blood, Sep. 1, 1994, vol. 84, No. 5, pp. 1402-1407.
Paul (ed),Fundamental Immunology, Raven Press (1993) p. 242.
Van Gool et al.,Blood, 83:176-183 (1994).
Valle et al.,Immunology, 69:531-534 (1990).
Razi-Wolf et al.,PNAS, 89:4210-4214 (1992).
Daikh et al.,J. Leukos. Biol., 62:156-162 (1997).
Newman et al., “Primatization of recombinant antibodies for iimmunotherapy of human diseases: a macaque/human chimeric antibody against human CD4,”Biotechnology, Nov. 1992, vol. 10, No. 11, pp. 1455-1460.
Van Gool et al., “Synergy between cyclosporin A and a monoclonal antibody to B7 in blcoking alloantigen-induced T-cell activation,” 1994,Blood, 83(1):176-183.
Nakajima et al., “Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule,” space,European Journal of Immunology, 25(11):3060-9.
Lenschow et al., “Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies,” 1995,Transplantation, 60(10):1171-8.
Lenschow et al., “Differential Effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the Nonobese Diabetic Mouse,” 1995,J Exp. Med., 181:1145-1155.
Kuchroo et al., “B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy,” 1995,Cell, 80:707-718.
Wettendorff et al., “Generation of humanized Fab fragments of B7-24 mAb, an antibody with potential use in prevention of graft rejection and development of graft-versus-host-disease,” 1995,Med Fac Landbouww. Univ. Gent., 60(4):2057-2063.
Alegre M., et al, “Effect of single amino acid mutation on the activating and immunosuppressive properties of a “Humanized” OKT3 monoclonal antibody,” J. Immunol., 1992, 148:3461-3468.
Armitage R.J., et al., “Molecular and biologial characterization of a murine ligand for CD40,” Nature, 1992, 357:80-82.
Azuma M., et al., “CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative Responses and Cytotoxicity Mediated by Small Resting T Lymphocytes,” J. Exp. Med., 1992, 175:353-360.
Azuma M., et al., “Functional Expression of B7/BB1 on Activated T Lymphocytes,” J. Exp. Med., 1993, 177:845-850.
Azuma M.D., et al., “B70 Antigen is a Second Ligand for CTLA-4 and CD28,” Nature, 1993, 366:76-79.
Ben-Nun A., et al., “The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis,” Eur. J. Immunol., 1981, 11:195-199.
Blazar B.R., t al., “Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct ffects on CD4+ and CD8+ T cells,” J Immunol., 1996, 157:3250-3259.
Boussiotis V.A., et al., “Activated human B lymphocytes express three CTLA-4 counter-receptors that co-stimulat T-Cell activation,” Proc. Natl. Acad. Sci., USA, 1993, 90:11059-11063.
Capon D.J., et al., “Designing CD4 immunoadhesins for AIDs therapy,” Nature, 1989, 337, 525-531.
Cohen J., “New protein steals the show as ‘costimulator’ of T cells,” Science, 1993, 262:844-845.
Cohen J., “Mounting a targeted strike on unwanted immune responses,” (news; comment), Science, 1992, 257:751.
Dautigny A., et al., “Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid,” FEBS Lett., 1985, 188(1):33-36.
De Boer M., et al., “Functional Characterization of a Novel Anti-B7 Monoclonal Antibody,” Eur. Journal of Immunology, 1992, 22:3071-3075.
Delabie J., et al., “Th B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines,” Blood, 1993, 82:2845-52.
Dermer G.B., et al., “Another Anniversary for the war on cancer,” Biotechnology, 1994, 12:320.
Dillman R.O., et al., “Antibodies as cytotoxic therapy,” 1994, J Clin Oncol., 12:1497-1515.
Dure F.H., et al., “The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease,” Research in Immunolgoy, 1994, 145(3), 200-205 & 244-249.
Durie F.H., et al., “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40,” Science, 1993, 261:1328-1330.
Engel et al, “The B7-2 (B70) costimulatory molecule expressed by monocytes and activted B lymphocytes is the CD86 differentiation antigen,” Blood, 1994, 84, 1402-1407.
F
Anderson Darrell R.
Brams Peter
Hanna Nabil
Biogen Idec Inc.
Gambel Phillip
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Treating intestinal inflammation with anti-CD80 antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating intestinal inflammation with anti-CD80 antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating intestinal inflammation with anti-CD80 antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862741